Enzymes in essential metabolic pathways are attractive targets for the treatment of bacterial diseases, but in many cases, the presence of homologous human enzymes makes them impractical candidates for drug development. Fumarate hydratase, an essential enzyme in the tricarboxylic acid (TCA) cycle, has been identified as one such potential therapeutic target in tuberculosis. We report the discovery of the first small molecule inhibitor, to our knowledge, of the Mycobacterium tuberculosis fumarate hydratase. A crystal structure at 2.0-Å resolution of the compound in complex with the protein establishes the existence of a previously unidentified allosteric regulatory site. This allosteric site allows for selective inhibition with respect to the homologous human enzyme. We observe a unique binding mode in which two inhibitor molecules interact within the allosteric site, driving significant conformational changes that preclude simultaneous substrate and inhibitor binding. Our results demonstrate the selective inhibition of a highly conserved metabolic enzyme that contains identical active site residues in both the host and the pathogen.
Because the tricarboxylic acid (TCA) cycle connects many pathways of cellular metabolism, preventing the function of this cycle through enzyme inhibition is an attractive strategy for targeting infectious agents (1). In Mycobacterium tuberculosis, experimental evidence (2) has suggested that fumarate hydratase, the essential enzyme responsible for the reversible conversion of fumarate to (L)-malate, is a vulnerable target. This vulnerability is in part due to the fact that, unlike other bacteria (such as Escherichia coli), M. tuberculosis expresses only one enzyme that performs this function (3). In addition to its role in metabolism under aerobic conditions, fumarate hydratase has also garnered interest because of the discovery of a flux toward the reverse TCA cycle under hypoxic conditions in nonreplicating M. tuberculosis (2, 4, 5). However, despite these discoveries, no small molecule inhibitor of the M. tuberculosis fumarate hydratase has been reported. The discovery of such an inhibitor would provide an important tool to begin probing the role of the TCA cycle in both actively replicating and nonreplicating bacteria.From the standpoint of drug development, however, targeting the M. tuberculosis fumarate hydratase poses a significant challenge, because the protein is highly evolutionarily conserved. In particular, the human and M. tuberculosis homologs share identical active site residues as well as 53% overall sequence identity (6, 7). Both homologs form a stable homotetramer containing four active sites, and every active site is composed of residues from three enzyme subunits. Each dumbbell-shaped subunit within the tetramer contains three domains: an N-terminal domain, a central domain, and a C-terminal domain (8-10). The N-and C-terminal domains are predominantly α-helical and linked by the central domain that consists of five tightly packed helices. The central domains of ...